Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer

Published: Saturday, Nov 07, 2015



Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Belani says at this juncture, there is no  one “winner" amongst these treatments.

Identifying a group of patients that best benefit from anti–PD-1 treatments will be the key to better understanding these agents, says  Belani.


Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Belani says at this juncture, there is no  one “winner" amongst these treatments.

Identifying a group of patients that best benefit from anti–PD-1 treatments will be the key to better understanding these agents, says  Belani.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x